Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers

• Main Authors: Gaozhi Chen (Author), Yuyan Bao (Author), Qiaoyou Weng (Author), Yingxin Zhao (Author), Xiaoyao Lu (Author), Lili Fu (Author), Lingfeng Chen (Author), Zhiguo Liu (Author), Xiaomin Zhang (Author), Guang Liang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In the past decades, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) had been proved as an effective treatment strategy for the patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, the tolerance for the EGFR-TKI always occurred after continuous administrati...